Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a Phase Ib trial conducted in Bougouni, Mali to evaluate the safety and immunogenicity of R21/Matrix-M in a single and two vial presentation, with different immunisation schedules, and when co-administered with EPI vaccines in African children.
Epistemonikos ID: ea5981e28ae13db0a9e58d01dc8a20b10d82ffe5
First added on: May 09, 2024